| Media Search: |
Dec 2013 Top 15 Social Networking Sites
Dec 2013 Top 15 Social Networking Sites.
By: quickhealth4u
Continue reading here:
Dec 2013 Top 15 Social Networking Sites - Video
Mark Zuckerberg announces the selling of shares of Facebook Monday.
Social networking has become a huge part of American life in the past decade or so. Starting Monday, Facebook, one of the most popular social networking websites will become a part of Standard & Poors 500-stock index.
At the close of trading on Friday, Facebook will be a part of that index.
That means that Mark Zuckerberg is selling more shares for Facebook. According to The NY Times, the social networking site is offering 70 million more shares to the public on Monday. This is the second offering since Facebook went public last year.
Those who missed out on the selling of shares in May 2012 will have a chance to buy stock in Facebook at the current price of $55.50. According to Forbes, the shares Zuckerberg is selling are worth $2.3 billion.
Though Zuckerberg will be selling millions of shares, it will only slightly loosen his control on the company. His voting rights will still be 60 percent.
The filing also said that Zuzkerberg intends on making a charitable gift of approximately 18 million shares, or $1 billion, this month. He plans to donate these shares to the Silicon Valley Community Foundation, a charity on which he has donated before.
The young company has come very far since 2004 and has the potential to make billions of dollars at the end of the trade day Monday.
image: Wikimedia Commons
Read the original post:
Facebook and Mark Zuckerberg to sell shares Monday
On Dec. 17, ePath Learning, Inc. announced that TMC, a global, integrated media company, has named eSource as a 2013 TMC Social Business Award Finalist sponsored by TMC's Customer magazine. eSource is a cloud-based social networking service that empowers employees to contribute, ask questions, share information, connect with colleagues, and search for experts throughout their organization. Employees can collaborate in teams and instantly see what others are working on, share information, post updates, and solve problems organically. The technology engages employees and augments informal learning opportunities. The functionality is similar to today's popular social networks, but eSource is private, secure, and supports multiple languages. ePath Learning offers eSource fully integrated into their ASAP learning management system or as a stand-alone cloud service. Furthermore, our mobile app allows eSource to be accessed on the go to keep enterprise users connected and contributing any time day or night.
"We are happy to once again be recognized as an innovator in social collaboration technology for business," stated Ms. Donna Lord, vice president, Sales and Marketing, ePath Learning, Inc. "Social collaboration technology is the catalyst that's driving organizational change. Social collaboration technology allows businesses to engage employees, business partners and even customers. Collaboration technology is rapidly becoming the driving force behind greater productivity, efficiency, and innovation, all of which contribute to optimizing performance. We're proud to be a leader in this dynamic people-centric approach to learning and development."
ePath Learning develops innovative, world-class software applications that improve training and human performance for organizations. Its portfolio of corporate learning services includes cloud-based learning portals, enterprise social networking technology, and custom eLearning development services. For more information, call us today at 908-722-6622, or go online to http://www.ePathLearning.com.
ePath Learning is a registered trademark and ePath Learning ASAP and eSource are service marks of ePath Learning, Inc.
Read this article:
READER SUBMITTED: ePath Learning, Inc. Named A Finalist Of The 2013 TMC Social Business Award
PUBLIC RELEASE DATE:
19-Dec-2013
Contact: Dr. Christian Mnz christian.muenz@uzh.ch 41-446-353-716 University of Zurich
More than 90 percent of all adults are carriers of the oncogenic Epstein-Barr Virus (EBV). Primary infection with this herpes virus as a young child is generally not linked to any symptoms, and usually offers life-long protection from its cancer-causing effect. However, for people who do not become infected with the virus until adolescence, the infection often leads to infectious mononucleosis (commonly known as glandular fever). Our immune systems can generally fend off this disease after a period of between one and several months. However, there is an increased risk of developing Hodgkin lymphoma at a later stage, a cancerous tumor of the lymphatic system. Immunologists from the University of Zurich have now discovered a risk factor that is in part responsible for the outbreak of infectious mononucleosis in young people.
Young natural killer cells combat primary infection
The researchers used an animal model to show that the loss of innate immune control by young natural killer cells can lead to infectious mononucleosis. "Young natural killer cells, which small children in particular have in abundance, seem to be especially suited to killing off the cells that multiply EBV", according to Christian Mnz, Professor of Experimental Immunology at the University of Zurich. "This weakens the primary infection and infectious mononucleosis does not break out".
Without the defense of the natural killer cells, EBV multiplies so dramatically during the primary infection phase that the aggressive response of the adaptive immune system chiefly of the T killer cells makes the infected person sick with infectious mononucleosis. "In the animal model we also observed weight loss and the increased occurrence of EBV-associated lymphomas. Consequently, natural killer cells seem to play a key role in the development of the primary infection with Epstein-Barr Virus". This is how Christian Mnz explains the results of the study.
Young people could benefit from a vaccination
Adolescents who are not yet carriers of EBV are at an increased risk of developing infectious mononucleosis. Christian Mnz's work group is currently examining vaccinations that could protect against EBV infection. This could prevent the outbreak of infectious mononucleosis and reduce the related risk of developing Hodgkin lymphoma.
###
Original post:
Young killer cells protect against infectious mononucleosis
By MALCOLM RITTER AP Science Writer
NEW YORK (AP) - Can an experimental drug developed to treat epilepsy block the AIDS virus? A preliminary lab study suggests it's possible, and researchers are eager to try it in people.
Scientists experimented with the drug after uncovering details of how they believe HIV cripples the immune system to bring on AIDS.
When tested in human tissues in the laboratory, the drug "works beautifully" to prevent HIV from destroying key cells of the immune system, said Dr. Warner Greene of the Gladstone Institutes in San Francisco. Those results appear in a paper by Greene and others published online Thursday by the journal Nature.
In that work, and a companion study published in Science, Greene and colleagues focus on how HIV kills vital CD4 cells of the disease-fighting immune system.
Researchers have long known it infects some CD4 cells and turns them into virus-producing factories, killing them in the process. But far more cells die without undergoing that transformation. What is going on in these "bystander"CD4 cells?
The new work provides evidence that HIV enters these cells but fails to produce a full-blown infection, and in response the cells trigger a lethal attack on themselves by the immune system.
It's "more of a suicide than a murder," Greene said. "I believe this is the major mechanism through which CD4 cells are depleted, which is the hallmark of AIDS."
The epilepsy drug, which is not on the market, blocks an enzyme that the research identified as playing a key role in that immune system attack.
Prior studies of the drug in people show it is safe, Greene said. So the researchers are talking to the drug company about testing it in people infected with HIV. No timeline for such studies has been set, he said.
Read more here:
Drug blocks HIV in lab study, human tests planned